Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle About Us menu options
Our Team
For Patients
Toggle For Patients menu options
About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
Multiple Myeloma
Amyloidosis
Other Plasma Cell Disorders
Toggle Other Plasma Cell Disorders menu options
Precursor Conditions to Multiple Myeloma
Myeloma Signs and Symptoms
Amyloidosis Signs and Symptoms
Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
Multiple Myeloma and Plasma Cell Disorder Treatment
Understanding and Managing Side Effects
Your First Visit
Toggle Your First Visit menu options
Self-Referral
Support Groups and Helpful Links
Frequently Asked Questions
Referring Physicians
Toggle Referring Physicians menu options
Refer a Patient
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 42 results
Author
[
Title
]
Type
Year
Filters:
First Letter Of Last Name
is
J
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Mark T
,
Jayabalan D
,
Coleman M
,
Pearse RN
,
Y Wang L
,
Lent R
,
Christos PJ
,
Lee JW
,
Agrawal YP
,
Matthew S
et al.
. 2008.
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
.
Br J Haematol. 143(5):654-60.
B
Niesvizky R
,
Jayabalan DS
,
Christos PJ
,
Furst JR
,
Naib T
,
Ely S
,
Jalbrzikowski J
,
Pearse RN
,
Zafar F
,
Pekle K
et al.
. 2008.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
.
Blood. 111(3):1101-9.
Niesvizky R
,
Jayabalan DS
,
Christos PJ
,
Furst JR
,
Naib T
,
Ely S
,
Jalbrzikowski J
,
Pearse RN
,
Zafar F
,
Pekle K
et al.
. 2008.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
.
Blood. 111(3):1101-9.
C
Ludwig H
,
Dimopoulos MA
,
Moreau P
,
Chng W-J
,
Goldschmidt H
,
Hajek R
,
Facon T
,
Pour L
,
Niesvizky R
,
Oriol A
et al.
. 2017.
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
.
Leuk Lymphoma. 58(10):2501-2504.
A Stewart K
,
S Rajkumar V
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Mihaylov GG
et al.
. 2015.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
.
N Engl J Med. 372(2):142-52.
Dimopoulos MA
,
A Stewart K
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel D
,
Mihaylov GG
,
Goranova-Marinova V
et al.
. 2017.
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
.
Br J Haematol. 177(3):404-413.
Dimopoulos MA
,
Goldschmidt H
,
Niesvizky R
,
Joshua D
,
Chng W-J
,
Oriol A
,
Orlowski RZ
,
Ludwig H
,
Facon T
,
Hajek R
et al.
. 2017.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
.
Lancet Oncol. 18(10):1327-1337.
Avet-Loiseau H
,
Fonseca R
,
Siegel D
,
Dimopoulos MA
,
Spicka I
,
Masszi T
,
Hajek R
,
Rosiñol L
,
Goranova-Marinova V
,
Mihaylov G
et al.
. 2016.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
.
Blood. 128(9):1174-80.
Goldschmidt H
,
Moreau P
,
Ludwig H
,
Niesvizky R
,
Chng W-J
,
Joshua D
,
Weisel K
,
Spencer A
,
Orlowski RZ
,
Feng S
et al.
. 2018.
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
.
Leuk Lymphoma. 59(6):1364-1374.
Dimopoulos MA
,
Stewart AK
,
Masszi T
,
Špička I
,
Oriol A
,
Hájek R
,
Rosiñol L
,
Siegel D
,
Mihaylov GG
,
Goranova-Marinova V
et al.
. 2017.
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
.
Blood Cancer J. 7(4):e554.
Ely S
,
Forsberg P
,
Ouansafi I
,
Rossi A
,
Modin A
,
Pearse R
,
Pekle K
,
Perry A
,
Coleman M
,
Jayabalan D
et al.
. 2017.
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
.
Clin Lymphoma Myeloma Leuk. 17(12):825-833.
Jurczyszyn A
,
Nahi H
,
Avivi I
,
Gozzetti A
,
Niesvizky R
,
Yadlapati S
,
Jayabalan DS
,
Robak P
,
Pika T
,
Andersen KT
et al.
. 2016.
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
.
Br J Haematol. 175(5):884-891.
Jurczyszyn A
,
Nahi H
,
Avivi I
,
Gozzetti A
,
Niesvizky R
,
Yadlapati S
,
Jayabalan DS
,
Robak P
,
Pika T
,
Andersen KT
et al.
. 2016.
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
.
Br J Haematol. 175(5):884-891.
Jurczyszyn A
,
Nahi H
,
Avivi I
,
Gozzetti A
,
Niesvizky R
,
Yadlapati S
,
Jayabalan DS
,
Robak P
,
Pika T
,
Andersen KT
et al.
. 2016.
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
.
Br J Haematol. 175(5):884-891.
Gay F
,
S Rajkumar V
,
Coleman M
,
Kumar S
,
Mark T
,
Dispenzieri A
,
Pearse R
,
Gertz MA
,
Leonard J
,
Lacy MQ
et al.
. 2010.
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
.
Am J Hematol. 85(9):664-9.
E
Rosenbaum C
,
Jasielec J
,
Laubach J
,
Prada CPaba
,
Richardson P
,
Jakubowiak AJ
. 2013.
Evolving strategies in the initial treatment of multiple myeloma.
.
Semin Oncol. 40(5):592-601.
Rosenbaum C
,
Jasielec J
,
Laubach J
,
Prada CPaba
,
Richardson P
,
Jakubowiak AJ
. 2013.
Evolving strategies in the initial treatment of multiple myeloma.
.
Semin Oncol. 40(5):592-601.
G
Wei X
,
M Calvo-Vidal N
,
Chen S
,
Wu G
,
Revuelta MV
,
Sun J
,
Zhang J
,
Walsh MF
,
Nichols KE
,
Joseph V
et al.
. 2018.
Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.
.
Cancer Res. 78(10):2747-2759.
Wei X
,
M Calvo-Vidal N
,
Chen S
,
Wu G
,
Revuelta MV
,
Sun J
,
Zhang J
,
Walsh MF
,
Nichols KE
,
Joseph V
et al.
. 2018.
Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.
.
Cancer Res. 78(10):2747-2759.
Wei X
,
M Calvo-Vidal N
,
Chen S
,
Wu G
,
Revuelta MV
,
Sun J
,
Zhang J
,
Walsh MF
,
Nichols KE
,
Joseph V
et al.
. 2018.
Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.
.
Cancer Res. 78(10):2747-2759.
H
A Stewart K
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Niesvizky R
,
Jakubowiak AJ
et al.
. 2016.
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
.
J Clin Oncol. 34(32):3921-3930.
Jhaveri KD
,
Niesvizky R
. 2017.
High-Cutoff Hemodialysis in Myeloma Cast Nephropathy.
.
JAMA. 318(21):2085-2086.
I
Nayar U
,
Sadek J
,
Reichel J
,
Hernandez-Hopkins D
,
Akar G
,
Barelli PJ
,
Sahai MA
,
Zhou H
,
Totonchy J
,
Jayabalan D
et al.
. 2017.
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.
.
J Clin Invest. 127(6):2066-2080.
Geyer JT
,
Niesvizky R
,
Jayabalan DS
,
Mathew S
,
Subramaniyam S
,
Geyer AI
,
Orazi A
,
Ely SA
. 2014.
IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.
.
Mod Pathol. 27(3):375-81.
Castillo JJ
,
Jurczyszyn A
,
Brozova L
,
Crusoe E
,
Czepiel J
,
Davila J
,
Dispenzieri A
,
Eveillard M
,
Fiala MA
,
Ghobrial IM
et al.
. 2017.
IgM myeloma: A multicenter retrospective study of 134 patients.
.
Am J Hematol. 92(8):746-751.
1
(current)
2
next ›
last »